Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are studying finerenone to find a better long-term treatment for children and young adults with heart failure and left ventricular systolic dysfunction LVSD, a condition where the hearts left side is weak and cannot pump blood well. The study aims to understand how safe finerenone is and how well it works when added to standard heart failure treatments in participants from newborns up to 18 years old. Participants will receive finerenone treatment for up to 9 months while continuing their usual heart failure care. The study includes children and young adults who joined an earlier finerenone trial and newly enrolled newborns under 6 months old with LVSD. Participants will attend at least six visits during the treatment period, where various health checks and tests will be done. During the study visits, researchers will measure vital signs, take blood samples, perform heart tests like electrocardiograms and echocardiograms, and ask about medication use and any medical problems. Parents or guardians of newborns and infants will provide feedback on how acceptable the study drug formulation is. After finishing treatment, participants will have a follow-up health check about one month later. The study will monitor safety by tracking medical problems and changes in potassium levels, blood pressure, and kidney function.
Actively Recruiting
Researchers are studying children with heart failure caused by left ventricular systolic dysfunction LVSD, a condition where the heart cannot pump enough blood. The goal is to see if the drug finerenone, which blocks a protein related to inflammation and scarring, can help the heart pump better compared to a placebo. This is the first study to test finerenone specifically in children with heart failure and LVSD, focusing on safety and effects on heart stress markers. Participants aged 6 months to under 18 years will be randomly assigned to receive either finerenone or a placebo for about three months, alongside their regular heart failure treatments. After this period, those who qualify may join an additional nine-month open-label phase where all receive finerenone. Those who do not join the extension will have a follow-up visit one month after finishing treatment. During the study, participants will visit the clinic at least three times for physical exams, heart tests including ECG and echocardiogram, blood tests, and measurements like blood pressure and heart rate. Researchers will track changes in a heart stress protein called NT-proBNP, monitor safety by recording any adverse events, and measure other heart function markers. The total study duration can be up to about a year including the extension and follow-up.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
Researchers are evaluating two different chemotherapy regimens following long-course chemoradiation therapy for patients with distal rectal cancer. The study aims to compare fluoropyrimidine alone versus fluoropyrimidine combined with oxaliplatin in consolidation chemotherapy to determine their effect on tumor response and the potential for organ preservation through a Watch and Wait strategy. This multi-center trial focuses on patients with MRI-defined distal rectal tumors classified as mrT2-3N0-1 and assesses tumor response after 12 weeks from radiotherapy completion. Participants receive 54 Gy of radiotherapy with daily capecitabine during treatment, followed by consolidation chemotherapy starting one week after radiotherapy ends. One group receives fluoropyrimidine alone, while the other receives fluoropyrimidine plus oxaliplatin, with dosing schedules of either mFOLFOX6 or CAPOX over approximately 12 weeks. Tumor response is centrally reviewed at 12 and 18 weeks, with decisions about continuing organ preservation or proceeding to surgery made by a central committee blinded to treatment assignment. Throughout the study, participants undergo clinical exams, endoscopic assessments, and high-resolution MRI to monitor tumor changes and response. The primary outcome is the decision to proceed with the Watch and Wait approach based on clinical complete response at 18 weeks post-radiotherapy. Secondary outcomes include surgery-free survival, total mesorectal excision-free survival, distant metastases-free survival, local regrowth-free survival, and colostomy-free survival assessed over three years. The study includes ongoing safety monitoring and follow-up to evaluate long-term outcomes.
Actively Recruiting
Researchers are evaluating a new medicine called NNC6019-0001 to see if it can reduce the risk of heart-related death and illness in people with transthyretin amyloid cardiomyopathy ATTR-CM, a condition that affects the heart. This phase 3 study compares NNC6019-0001 to a placebo, with participants continuing their regular heart treatments as advised by their doctors. The study aims to better understand cardiovascular outcomes in this patient group over time. Participants will receive either NNC6019-0001 or a placebo intravenously. Both groups may continue with their usual standard of care treatments as recommended by their healthcare providers. The treatment is given in a parallel design where each participant is randomly assigned to one of the two groups. The study will last up to approximately four years, allowing long-term observation of effects. During the study, participants will be regularly monitored through various assessments including questionnaires about heart health, walking tests, and measurements of heart function and biomarkers. Researchers will track cardiovascular deaths, hospital visits, and heart failure events among other outcomes. Safety and health status will be followed closely throughout the study period to evaluate the impact of the treatment compared to placebo.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational, cross-sectional study with a control group to develop and evaluate a national database in Brazil focused on Parkinsons disease PD. This database will collect detailed clinical, epidemiological, motor, and non-motor information to better understand PD and support research advancement. The study aims to compare data from individuals with PD to healthy controls, contributing to improved characterization of PD stages and aiding the development of clinical tools and methods. The study involves two groups one with participants diagnosed with Parkinsons disease and a control group of neurologically healthy individuals. Data collection includes questionnaires, clinical scales, and motor activity tests. Personal identifying information will be removed to protect privacy before storing data in a research repository. The database will be accessible to both national and international researchers. Participants will undergo various assessments including motor function tests and clinical evaluations such as the MDS-Unified Parkinsons Disease Rating Scale. Additional data collected will include demographics, medical history, cognitive function, and visual acuity. Researchers will analyze these data to contrast the groups and characterize PD stages. The study is expected to provide valuable insights and support future clinical research over a long-term period.
1-10 of 14
1